7 results on '"Xu, Huaxiang"'
Search Results
2. The role of collagen in cancer: from bench to bedside
- Author
-
Xu, Shuaishuai, Xu, Huaxiang, Wang, Wenquan, Li, Shuo, Li, Hao, Li, Tianjiao, Zhang, Wuhu, Yu, Xianjun, and Liu, Liang
- Published
- 2019
- Full Text
- View/download PDF
3. The optimal duration of capecitabine plus temozolomide in patients with well‐differentiated pancreatic NETs with or without maintenance therapy.
- Author
-
Gao, Heli, Dong, Jia, Zhang, Wuhu, Xu, Huaxiang, Ye, Longyun, Li, Hao, Wang, Wenquan, Liu, Liang, and Yu, Xianjun
- Subjects
TEMOZOLOMIDE ,HAND-foot syndrome ,NEUROENDOCRINE tumors ,PROGRESSION-free survival ,DISEASE progression ,TREATMENT duration - Abstract
Background: The optimal duration of capecitabine combined with temozolomide (CapTem) for metastatic pancreatic neuroendocrine tumours (PanNETs) remains controversial. The present study aimed to assess the activity and safety of prolonged CapTem and Cap maintenance therapy in patients with metastatic PanNETs. Methods: Retrospective real‐world data of 94 patients with metastatic PanNETs were obtained from one cancer centre. Fifteen patients were treated with Cap maintenance therapy after fixed 12–13 cycles of CapTem (group I), 44 patients were treated with prolonged CapTem until disease progression (group II), and 35 patients were treated with fixed 12–13 cycles of CapTem (group III). Results: The mean ± SE follow‐up period was 41.79 ± 26.31 months. The median CapTem treatment duration was 12 months in group I and 14 months in group II. The median time to best partial response was 12 months both in groups I and group II. The objective response rates of groups I and II were significantly higher than those of group III (73.3%, 41.9%, and 20%, respectively, p =.002). The median progression‐free survival (mPFS) of group I and group II was significantly higher than that of group III (35 months, 26 months vs. 19 months, p <.001). Safety analysis of the three groups indicated rare events of grade 3–4 toxicities, with nausea, vomiting, fatigue, and anaemia being the most common adverse effects. Conclusions: Patients with PanNETs who responded well to CapTem treatment may benefit from prolonged CapTem and Cap maintenance therapy after fixed cycles. Prospective studies are encouraged to further explore the prolonged CapTem treatment and maintenance therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Robust Validation and Comprehensive Analysis of a Novel Signature Derived from Crucial Metabolic Pathways of Pancreatic Ductal Adenocarcinoma.
- Author
-
Gu, Wenchao, Mo, Shaocong, Wang, Yulin, Kawabata-Iwakawa, Reika, Zhang, Wei, Yang, Zongcheng, Sun, Chenyu, Tsushima, Yoshito, Xu, Huaxiang, and Nakajima, Takahito
- Subjects
PANCREATIC tumors ,CANCER relapse - Abstract
Simple Summary: Pancreatic ductal adenocarcinoma (PDAC) has a high mortality rate and a poor prognosis. To solve the above limitations of multiomics studies of metabolism in PDAC and optimize the prognosis of PDAC clinically, we demonstrated a 16-gene prognostic signature based on the metabolic pathways called gbcxMRS. The prognostic value varied in six public datasets and our own data cohort in Shanghai Cancer Center by RT-PCR. Notably, gbcxMRS also accurately predicted poor PDAC subtypes and recurrence. It also highly associated with immune infiltration cells. Furthermore, high gbcxMRS may indicate high sensitivity to irinotecan, docetaxel, and CTLA4 inhibitor immunotherapy. Pancreatic ductal adenocarcinoma (PDAC) is a malignant tumor with a dismal prognosis. PDAC have extensively reprogrammed metabolic characteristics influenced by interactions with normal cells, the effects of the tumor microenvironment and oncogene-mediated cell-autonomous pathways. In this study, we found that among all cancer hallmarks, metabolism played an important role in PDAC. Subsequently, a 16-gene prognostic signature was established with genes derived from crucial metabolic pathways, including glycolysis, bile acid metabolism, cholesterol homeostasis and xenobiotic metabolism (gbcx). The signature was used to distinguish overall survival in multiple cohorts from public datasets as well as a validation cohort followed up by us at Shanghai Cancer Center. Notably, the gbcx-related risk score (gbcxMRS) also accurately predicted poor PDAC subtypes, such as pure-basal-like and squamous types. At the same time, it also predicted PDAC recurrence. The gbcxMRS was also associated with immune cells, especially CD8 T cells, Treg cells. Furthermore, a high gbcxMRS may indicate high drug sensitivity to irinotecan and docetaxel and CTLA4 inhibitor immunotherapy. Taken together, these results indicate a robust and reproducible metabolic-related signature based on analysis of the overall pathogenesis of pancreatic cancer, which may have excellent prognostic and therapeutic implications for PDAC. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Distinct clinicopathological and prognostic features of insulinoma with synchronous distant metastasis.
- Author
-
Gao, Heli, Wang, Wenquan, Xu, Huaxiang, Wu, Chuntao, Jin, Wei, Zhang, Shirong, Xu, Jinzhi, Ni, Quanxing, Yu, Xianjun, and Liu, Liang
- Abstract
The clinicopathological and prognostic features of insulinoma with synchronous metastases are unclear. This study aimed to verify the distinct clinicopathological and prognostic features of insulinoma with synchronous distant metastasis. Patients with pancreatic neuroendocrine tumor (PanNET) were retrospectively enrolled and divided into cohort 1 (Fudan University Shanghai Cancer Center) and cohort 2 (Surveillance, Epidemiology, and End Results Program database). Both cohorts were further divided into three subgroups: insulinoma, nonfunctioning pancreatic neuroendocrine tumor (NF-PanNET), and non-insulinoma functioning pancreatic neuroendocrine tumor (NiF-PanNET). Cohorts 1 and 2 comprised 505 and 2761 patients (1566 M0 patients and 1195 M1 patients), respectively. In cohort 1 and cohort 2 M0 subgroup, insulinoma showed longer disease-free survival, overall survival (OS), and disease-specific survival (DSS) than NiF-PanNET and NF-PanNET (not reached vs. 48 and 60months, p < 0.001; 183months vs. 87 and 109months, p < 0.001; 247months vs. 121 and 140months, p = 0.002). However, in cohort 2 M1, the mDSS for metastatic insulinoma was shorter than that for NiF-PanNET (31months vs. 61months, p = 0.045), while the mDSS and mOS were similar to those for NF-PanNET. The percentage of T1 and N0 patients was similar between the metastatic insulinoma subgroup and NiF-PanNET and NF-PanNET subgroups. The Ki-67 index and recurrence had a positive linear relationship only for NiF-PanNET and NF-PanNET (p = 0.009). Insulinoma with synchronous metastasis showed clinicopathological and prognostic characteristics similar to those of NF-PanNET. Metastatic insulinoma had worse prognosis than non-insulinoma F-PanNET. These findings may help in the clinical management of metastatic insulinoma. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
6. Prognostic value of γ‐glutamyltransferase‐to‐albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery.
- Author
-
Li, Shuo, Xu, Huaxiang, Wu, Chuntao, Wang, Wenquan, Jin, Wei, Gao, Heli, Li, Hao, Zhang, Shirong, Xu, Jinzhi, Zhang, Wuhu, Xu, Shuaishuai, Li, Tianjiao, Ni, Quanxing, Yu, Xianjun, and Liu, Liang
- Subjects
- *
CA 19-9 test , *PANCREATIC surgery , *PROGNOSIS , *LIVER function tests , *SURVIVAL analysis (Biometry) , *OBSTRUCTIVE jaundice - Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with poor prognosis. Many preoperative biomarkers can predict postoperative survival of PDAC patients. In this study, we created a novel ratio index based on preoperative liver function test, γ‐glutamyltransferase‐to‐albumin ratio (GAR), and evaluated its prognostic value in predicting clinical outcomes of PDAC patients following radical surgery. We retrospectively enrolled 833 PDAC patients who had underwent radical surgery at our institution between January 2010 and January 2017. Patients were divided into two groups according to the cut‐off value of GAR. Univariate and multivariate survival analysis between the groups were evaluated. TNM stage, GAR, preoperative serum carbohydrate antigen 19‐9 (CA19‐9) and tumor differentiation were combined to generate a more accurate prognostic model. The optimal cut‐off value of GAR was 0.65. Significant correlations were found between GAR and tumor location, tumor size, vascular invasion, obstructive jaundice, biliary drainage and parameters of liver function test. Univariate and multivariate analysis showed that high level of GAR independently predicted poorer postoperative overall survival (OS, P < 0.001) and recurrence‐free survival (RFS, P < 0.001). Subgroup analysis demonstrated that GAR was predictive of survival in patients without biliary obstruction or severely impaired liver function. In addition, integration of GAR, preoperative serum CA19‐9, and tumor differentiation into TNM staging system could better stratify the prognosis for PDAC patients compared with TNM stage alone. Our study demonstrates that preoperative GAR is an independent prognostic factor for prediction of surgical outcomes in PDAC patients. Combination of TNM stage, GAR, preoperative serum CA19‐9, and tumor differentiation can enhance the prognostic accuracy. We created a novel ratio index, γ‐glutamyltransferase‐to‐albumin ratio (GAR), based on preoperative liver function test of patients with pancreatic ductal adenocarcinoma (PDAC). Preoperative GAR is an independent prognostic factor for prediction of surgical outcomes in PDAC patients. Combination of TNM stage, GAR, preoperative serum CA19‐9, and tumor differentiation can enhance the prognostic accuracy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. Metabolic tumor burden: A new promising way to reach precise personalized therapy in PDAC.
- Author
-
Xiang, Jinfeng, Liu, Liang, Wang, Wenquan, Xu, Huaxiang, Wu, Chuntao, Xu, Jin, Liu, Chen, Long, Jiang, Ni, Quanxing, and Yu, Xianjun
- Subjects
- *
PANCREATIC cancer treatment , *PANCREATIC cancer , *INDIVIDUALIZED medicine , *ADENOCARCINOMA , *METABOLOMICS , *HEALTH outcome assessment , *MEDICAL decision making , *PROGNOSIS - Abstract
Pancreatic cancer is currently one of the deadliest solid malignancies and pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. In the past decade, diagnostics and surgical techniques for PDAC have been evolving steadily; however, clinical outcomes of patients with PDAC have shown little, if any, improvement. Subgroup classification based on accurate prediction of prognosis in patients with pancreatic cancer is important for treatment selection and clinical decision-making. The traditional method to evaluate prognosis relies on the TNM staging system, but it may not reflect the true status of every patient due to individual biological differences. Metabolomics is a field of study that involves the identification and quantification of metabolites present in a biological system. Analysis of metabolic differences between cancerous and noncancerous tissues can provide novel insights into tumor biology that are closely associated with disease prognosis and diagnosis. Therefore, evaluation of metabolic tumor burden may improve the accuracy of the clinical decision-making process, thereby facilitating optimization of the treatment strategies for pancreatic cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.